Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats

Gabor Imre; Dirk S. Fokkema; Gert J. Ter Horst

doi:10.1016/j.ejphar.2006.06.037

Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats

Gabor Imre^*, Dirk S. Fokkema, Gert J. Ter Horst

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

19 Citations (Scopus)

Abstract

Acute treatment with LY354740 {1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate}, a potent and selective agonist for group 11 metabotropic glutamate receptors (mGlu2/3), has previously been shown to block some schizophrenia-like effects of N-methyl-D-aspartate (NMDA) receptor antagonists, suggesting a novel therapeutic strategy for schizophrenia. The present study examined the effects of subchronic pretreatment with LY354740 (0.3, 3 and 10 mg/kg i.p.) on ketamine-evoked (12 mg/kg s.c.) prepulse inhibition deficits, hyperlocomotion and c-fos expression. At all doses, LY354740 failed to reverse both behavioral and neuronal effects of the ketamine. These results therefore do not support the putative antipsychotic role of LY354740. (c) 2006 Elsevier B.V All rights reserved.

Original language	English
Pages (from-to)	77-81
Number of pages	5
Journal	European Journal of Pharmacology
Volume	544
Issue number	1-3
DOIs	https://doi.org/10.1016/j.ejphar.2006.06.037
Publication status	Published - 21-Aug-2006

Keywords

mGlu2/3 receptor
prepulse inhibition
locomotion
c-fos expression
schizophrenia
METABOTROPIC GLUTAMATE RECEPTORS
GROUP-II
PREFRONTAL CORTEX
PREPULSE INHIBITION
LOCOMOTOR-ACTIVITY
DOPAMINE RELEASE
AGONIST
PHENCYCLIDINE
SCHIZOPHRENIA
MODELS

Access to Document

10.1016/j.ejphar.2006.06.037

Cite this

@article{6a57a0d8d99a4f5ab9b142f1b24b8b1b,

title = "Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats",

abstract = "Acute treatment with LY354740 {1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate}, a potent and selective agonist for group 11 metabotropic glutamate receptors (mGlu2/3), has previously been shown to block some schizophrenia-like effects of N-methyl-D-aspartate (NMDA) receptor antagonists, suggesting a novel therapeutic strategy for schizophrenia. The present study examined the effects of subchronic pretreatment with LY354740 (0.3, 3 and 10 mg/kg i.p.) on ketamine-evoked (12 mg/kg s.c.) prepulse inhibition deficits, hyperlocomotion and c-fos expression. At all doses, LY354740 failed to reverse both behavioral and neuronal effects of the ketamine. These results therefore do not support the putative antipsychotic role of LY354740. (c) 2006 Elsevier B.V All rights reserved.",

keywords = "mGlu2/3 receptor, prepulse inhibition, locomotion, c-fos expression, schizophrenia, METABOTROPIC GLUTAMATE RECEPTORS, GROUP-II, PREFRONTAL CORTEX, PREPULSE INHIBITION, LOCOMOTOR-ACTIVITY, DOPAMINE RELEASE, AGONIST, PHENCYCLIDINE, SCHIZOPHRENIA, MODELS",

author = "Gabor Imre and Fokkema, {Dirk S.} and {Ter Horst}, {Gert J.}",

note = "Article J",

year = "2006",

month = aug,

day = "21",

doi = "10.1016/j.ejphar.2006.06.037",

language = "English",

volume = "544",

pages = "77--81",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "ELSEVIER SCIENCE BV",

number = "1-3",

}

TY - JOUR

T1 - Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats

AU - Imre, Gabor

AU - Fokkema, Dirk S.

AU - Ter Horst, Gert J.

N1 - Article J

PY - 2006/8/21

Y1 - 2006/8/21

N2 - Acute treatment with LY354740 {1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate}, a potent and selective agonist for group 11 metabotropic glutamate receptors (mGlu2/3), has previously been shown to block some schizophrenia-like effects of N-methyl-D-aspartate (NMDA) receptor antagonists, suggesting a novel therapeutic strategy for schizophrenia. The present study examined the effects of subchronic pretreatment with LY354740 (0.3, 3 and 10 mg/kg i.p.) on ketamine-evoked (12 mg/kg s.c.) prepulse inhibition deficits, hyperlocomotion and c-fos expression. At all doses, LY354740 failed to reverse both behavioral and neuronal effects of the ketamine. These results therefore do not support the putative antipsychotic role of LY354740. (c) 2006 Elsevier B.V All rights reserved.

AB - Acute treatment with LY354740 {1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate}, a potent and selective agonist for group 11 metabotropic glutamate receptors (mGlu2/3), has previously been shown to block some schizophrenia-like effects of N-methyl-D-aspartate (NMDA) receptor antagonists, suggesting a novel therapeutic strategy for schizophrenia. The present study examined the effects of subchronic pretreatment with LY354740 (0.3, 3 and 10 mg/kg i.p.) on ketamine-evoked (12 mg/kg s.c.) prepulse inhibition deficits, hyperlocomotion and c-fos expression. At all doses, LY354740 failed to reverse both behavioral and neuronal effects of the ketamine. These results therefore do not support the putative antipsychotic role of LY354740. (c) 2006 Elsevier B.V All rights reserved.

KW - mGlu2/3 receptor

KW - prepulse inhibition

KW - locomotion

KW - c-fos expression

KW - schizophrenia

KW - METABOTROPIC GLUTAMATE RECEPTORS

KW - GROUP-II

KW - PREFRONTAL CORTEX

KW - PREPULSE INHIBITION

KW - LOCOMOTOR-ACTIVITY

KW - DOPAMINE RELEASE

KW - AGONIST

KW - PHENCYCLIDINE

KW - SCHIZOPHRENIA

KW - MODELS

U2 - 10.1016/j.ejphar.2006.06.037

DO - 10.1016/j.ejphar.2006.06.037

M3 - Article

VL - 544

SP - 77

EP - 81

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -